410,440 Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 410,440 shares of the company’s stock, valued at approximately $7,868,000. Victory Capital Management Inc. owned approximately 0.52% of Viridian Therapeutics as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Great Point Partners LLC raised its position in Viridian Therapeutics by 50.0% in the third quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock valued at $17,062,000 after purchasing an additional 250,000 shares during the period. Lord Abbett & CO. LLC purchased a new stake in Viridian Therapeutics in the third quarter valued at $8,917,000. JPMorgan Chase & Co. raised its position in Viridian Therapeutics by 218.5% in the third quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company’s stock valued at $9,108,000 after purchasing an additional 274,641 shares during the period. Barclays PLC raised its holdings in shares of Viridian Therapeutics by 113.1% in the 3rd quarter. Barclays PLC now owns 125,397 shares of the company’s stock valued at $2,851,000 after buying an additional 66,550 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in shares of Viridian Therapeutics in the 3rd quarter valued at $788,000.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $15.92 on Friday. The business has a 50 day moving average of $17.43 and a two-hundred day moving average of $19.66. The company has a market cap of $1.30 billion, a P/E ratio of -3.69 and a beta of 1.05. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 52 week low of $11.40 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.05 million. As a group, analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on VRDN shares. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. TD Cowen started coverage on Viridian Therapeutics in a research note on Monday, November 25th. They set a “buy” rating for the company. Wells Fargo & Company reissued an “equal weight” rating and set a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Royal Bank of Canada boosted their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 17th. Finally, HC Wainwright reissued a “buy” rating and set a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $35.70.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.